A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Trial Details

NCT ID

NCT06208150

Phase

PHASE3

Sponsor

Janssen Research & Development, LLC

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

• Talquetamab
• Pomalidomide
• Teclistamab
• Elotuzumab
• Dexamethasone
• Bortezomib

Locations (sample)

• Clovis, California, United States|36.82523,-119.70292
• Santa Monica, California, United States|34.01949,-118.49138
• New Haven, Connecticut, United States|41.30815,-72.92816
• Newark, Delaware, United States|39.68372,-75.74966
• Hollywood, Florida, United States|26.0112,-80.14949

Key Eligibility Criteria

• Documented multiple myeloma as defined by the criteria below: (a) multiple myeloma diagnosis according to the international myeloma working group (…
• Relapsed or refractory disease as defined below: a) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed pr…
• Documented evidence of PD or failure to achieve a minimal response to the last line of therapy based on investigator's determination of response by…
• Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of adminis…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.